Electrode Position and the Clinical Outcome after Bilateral Subthalamic Nucleus Stimulation.
10.3346/jkms.2011.26.10.1344
- Author:
Sun Ha PAEK
1
;
Jee Young LEE
;
Han Joon KIM
;
Daehee KANG
;
Yong Hoon LIM
;
Mi Ryoung KIM
;
Cheolyoung KIM
;
Beom Seok JEON
;
Dong Gyu KIM
Author Information
1. Movement Disorder Center and Clinical Research Institute, Seoul National University Hospital, Seoul, Korea. brain@snu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Parkinson Disease;
Bilateral STN Stimulation;
Clinical Outcome;
Electrode Position;
Fused Images
- MeSH:
Adult;
Aged;
Antiparkinson Agents/adverse effects/*therapeutic use;
Combined Modality Therapy;
*Deep Brain Stimulation/adverse effects/instrumentation/methods;
*Electrodes, Implanted;
Female;
Humans;
Levodopa/adverse effects/therapeutic use;
Magnetic Resonance Imaging;
Male;
Middle Aged;
Parkinson Disease/drug therapy/*therapy;
Severity of Illness Index;
Subthalamic Nucleus/*physiology;
Treatment Outcome
- From:Journal of Korean Medical Science
2011;26(10):1344-1355
- CountryRepublic of Korea
- Language:English
-
Abstract:
We compared the surgical outcome with electrode positions after bilateral subthalamic nucleus (STN) stimulation surgery for Parkinson's disease. Fifty-seven patients treated with bilateral STN stimulations were included in this study. Electrode positions were determined in the fused images of preoperative MRI and postoperative CT taken at six months after surgery. The patients were divided into three groups: group I, both electrodes in the STN; group II, only one electrode in the STN; group III, neither electrode in the STN. Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn and Yahr stage, and activities of daily living scores significantly improved at 6 and 12 months after STN stimulation in both group I and II. The off-time UPDRS III speech subscore significantly improved (1.6 +/- 0.7 at baseline vs 1.3 +/- 0.8 at 6 and 12 months, P < 0.01) with least L-dopa equivalent daily dose (LEDD) (844.6 +/- 364.1 mg/day at baseline; 279.4 +/- 274.6 mg/day at 6 months; and 276.0 +/- 301.6 mg/day at 12 months, P < 0.001) at 6 and 12 months after STN deep brain stimulation (DBS) in the group I. Our findings suggest that the better symptom relief including speech with a reduced LEDD is expected in the patients whose electrodes are accurately positioned in both STN.
